Mayo Clinic Teams Up with California Startup on Biologics
Mayo Clinic is partnering with a California startup to ramp up production of cutting-edge drugs to treat rare and complex diseases. On Monday, the clinic announced that it has established a “strategic collaboration” with San Diego-based National Resilience Inc. to develop biologically-derived treatments for various illnesses.
According to a news release issued Monday, the two entities will focus on biologics, or drugs derived from cells, blood, or other components from living organisms. Mayo officials hope the partnership will fast-track therapies to clinical trials, and aid in scaling up for commercialization.
“We were excited by the National Resilience Inc. opportunity as they are/were building from scratch as we worked with them, which allowed us to have a voice in what was built and how,” said Julie Allickson, the Michael S. and Mary Sue Shannon Family Director of Mayo Clinic’s Center for Regenerative Medicine, in an email. “It also allowed us to secure benefits for Mayo including preferential access to manufacturing in terms of pricing and timelines.”
Rahul Singhvi, CEO of Resilience, said the collaboration “will establish Rochester, Minnesota, as a center of excellence for biomanufacturing cell and regenerative technologies.”
Allickson noted that Mayo chose to partner with an external business due to the clinic’s “diverse manufacturing needs … and the acute scarcity of manufacturing capacity nationally.”
The partnership will enable Mayo to tap into Resilience’s 11 manufacturing facilities across North America. In addition, the two entities have vowed to “attract biotech companies interested in sponsoring clinical trials at Mayo Clinic for novel regenerative biotherapeutics.”
Mayo is investing in Resilience as a result of the collaboration. “We invested early (in Series A) and then also in a subsequent Series B financing round,” Allickson said, though she declined to share precisely how much the clinic is providing.